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"It was the best of times, it was the warst of times, it was the age
ofwisdom, it was the age of foolishness, U was the epoch of belief,
it was the epoch of incredulity, it was the season of Light, it was
the season ofDarkness, it was the spring ofhope, it was the winter
ofdespaii; we had everything before us, we had nothing before us,
we were all going direct to Heaven, we were all going direct the
A tale of two cities, Charles Dickens 1859
Hemophilia is a rare hereditary bleeding disorder in
which clotting factor VIII (hemophilia A) or factor IX
(hemophilia B) is missing. Both hemophilia A ('classic
hemophilia') and hemophilia B ('Christmas disease') are
caused by defects on the X-chromosome. This implies
that, with few exceptions, all patients are men.
In normal hemostasis platelets will adhere and aggre-
gate at the site of a lesion thus forming a platelet plug
within minutes. Vasoactive amines released by the plate-
lets cause an arteriolar vasoconstriction that lasts for
hours and together with the platelet plug, effectively
stops bleeding. The plug needs to be Consolidated by a
fibrin mesh during this phase of reduced local blood
pressure by vasoconstriction. Activation of a cascade of
clotting factors will lead to the deposit of fibrin. In
hemophilia this fibrin formation by clotting factors activ-
ating each other is abnormal, because of a deficiency of
factor IX, or its co-enzyme factor VIII, which results in
bleeding tendency [80,117].
History
Over 1,500 years ago it was written in the Babylonic Tal-
mud that a woman who has lost her first two sons after
circumcision shall be exempt from the Obligation to have
the third son circumcised.
Babylonian Talmud, Tractate Yevamoth 64 b: "For it was taught: if
she circumcised her first son and he died, and a second one also
died, she must not circumcise her third child. These are the words
of Rebbc' (Rabbi Judah the Patriarch, redactor of the Mishneh, the
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second Century compilation of Jewish Law). 'Rabban Simeon ben
Gamiliel, however, said: she may circumcise the third child but
must not circumcise the fourth child" [113] see also [66].
This first description of hemophilia not only shows that
hemophilia was recognized in ancient times, but also il-
lustrates the severity of this disease. Early allusions to
hemophilia are found in the tenth Century medical hand-
book Al-Tasrif by the Moorish physician Khalaf ibn Ab-
bas Abu-al-Kasim (Albucasis) and in the codification of
Talmudic laws by Maimonides. Further references to
hemophilia are scarce until John Otto of Philadelphia
published his 'An account of a haemorrhagic disposition
existing in certain families' in 1803 [27,94]. Hemophilia
became widely known to the layman äs the "Royal Dis-
ease" during the fin de siecle äs it affected members of
the English, Prussian, Spanish and Russian Royal houses
[60]. In 1911, Bulloch and Fildes compiled the history of
hemophilia in a monumental monograph in which they
dealt with more than 1,000 references and case reports
and set out over 200 extensive pedigrees [27]. This work
has been described äs "... for students of hemophilia at
once their Shakespeare for its drama and its human
warmth, and their Bible for its towering authority" [60].
Until only recently, hemophilia remained a crippling
disease with a low life expectancy [59,70], primarily due
to the lack of clotting factor preparations of a sufficient
concentration to reach adequate hemostatic levels follow-
ing transfusion. This bleak outlook for hemophilia pa-
tients was dramatically improved by the introduction of
purified clotting factors in the 1960s.
Epidemiology
The prevalence of hemophilia in industrialized countries
has been reported at 13-18 per 100,000 males [71,104,
123]. Hemophilia A is five to six times äs common äs
hemophilia B [71,123]; other clotting factor deficiencies
with a bleeding tendency are extremely rare and account
for less than one percent of the cases [123].
The observed occurence of hemophilia is the resultant
of the prevalence at birth and the mortality rate. We have
estimated the prevalence at birth from data obtained by
a survey of all 1,162 hemophilia patients registered in the
Netherlands [106]. This is illustrated in Fig. l, which
shows the prevalence per age group. A steady decline of
the age-specific prevalence occurs after age 40. This defi-
cit of older patients can only be explained by excess mor-
tality in the past. The plateau of 20.6 per 100,000 males
approximates the prevalence at birth, which is 28% more
than the observed prevalence in the Netherlands.
Because of the availability of clotting products, he-
mophilia patients may now expect to live well into their
sixties [70,112]. Inevitably, this will lead to an increase in
the number of patients living; with the current small ex-
cess mortality (aside from mortalities resulting from
AIDS), we estimated an increase in the total number of
patients of about 20% to occur in one or two generations
[106]. Prenatal diagnosis and selective abortion will not
substantially affect these figures, since only a rninority of
carriers choose for this Option, äs we found in a survey
of 549 female relatives of hemophilia patients [141]. For
many of these women hemophilia was no longer a disease
of such severity that it warranted an abortion. In the
future, the number of patients will increase even further,
since more and more patients marry and have families
[106].
A hereditary disease with excess mortality can only be
maintained in the population by the arising of new muta-
tions. As J. B. S. Haldane pointed out: if we thought there
were no mutations, the present number of hemophilia pa-
tients could only be explained by assuming that "all Eng-
lishmen at the time of the Norman conquest would have
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Fig. 1. The prevalence of hemophilia. In each age group the num-
ber of patients is divided by the total number of men in the Nether-
lands of that age (data from the Central Bureau of Statistics). In-
formation was available for 80% (935) of the patients, of whom
384 had severe hemophilia; the prevalence data have been extended
to all 1,162 (reprinted from [106])
been haemophiliacs" [56]. In hemophilia, about one
third of all cases are isolated patients, i.e. the first patient
in the family. These patients are likely to be the result of
a recent mutation, e.g. in their mothers or grandparents.
There are strong indications that the mutation rate in
males (producing carrier daughters) is 2 to 10 times äs
high äs the mutation rate in females (producing sons with
hemophilia or carrier daughters) [56,108,147]. The mean
mutation rate for hemophilia has been estimated at 1-5
per 100,000, implying that out of a population of 100,000
homozygous normal individuals, males and females, one
to five of the offspring will carry the gene for hemo-
philia.
Signs and Symptoms
The severity of the bleeding tendency is determined by the
residual clotting factor activity. This residual activity is
fairly constant within an individual and breeds true with-
in families. When there is no or less than one percent (i.e.
0.01 lU/ml) clotting factor activity present, the disease is
defined äs severe hemophilia. Clinically, hemophilia A
and B are identical [101].
Most bleedings in severe hemophilia occur spontan-
eously in the larger joints and in muscles. In mild hemo-
philia (5-40% FVIII or FIX) bleeding usually does not
occur except after trauma; moderately severe hemophilia
(1—5% FVIII or FIX) has clinical features in between
severe and mild hemophilia and may show the largest in-
dividual Variation. In severe hemophilia the first signs
usually appear at an early age (8 to 12 months) when the
child begins to move around. Symptoms will be bruising,
nose bleeding, bleedings after minor injuries or joint
bleedings. Typically, bleeding does not occur during the
neonatal period. Bleeding in the first days of life, notably
from the umbilicus, is characteristic of another inherited
clotting factor deficiency: homozygous factor XIII defi-
ciency. The diagnosis in the less severely affected patients,
who seldom bleed unchallenged, is usually made at an
older age after tooth extraction, surgery or trauma [16,
82,133].
Repeated bleeding in joints causes arthropathy, the
major chronic complication of hemophilia. The handi-
cap is often worsened by muscle atrophy because of
muscle bleedings. Therefore, the distinguishing features
of an older hemophilia patient are posture and gait, far
more than evidence of acute bleedings.
Treatment
A succesful effect of blood transfusion for postoperative
bleeding in a hemophilic boy has been described äs early
äs 1840 by Lane [69]. The yield of whole blood or plasma
transfusion, however, usually proved insufficient for con-
trol of bleeding and the transfusion easily led to circula-
tory overload. Attempts to increase the factor VIII activ-
ity in preparations made from human plasma came about
in the 1950s [14,67,126]. In 1964, Judith Pool and co-
woikers reported a simple and reliable method to purify
clotting factor VIII äs a cryoprecipitate from human plas-
ma [96]. At approximately the same time blood products
rieh in factor IX, äs well äs factors II, VII and X, became
available for the treatment of patients with hemophilia B
[10,13,125]. Dutch factor VIII and IX preparations were
used from 1967 on [79,88]. These developments opened
the possibilities of modern hemophilia treatment by ad-
equate replacement therapy and revolutionalized hemo-
philia care.
Replacement therapy in hemophilia A consists of the
intravenous infusion of cryoprecipitate or factor VIII
concentrate; for hemophilia B, prothrombin complex
concentrate is used (PPSB; which contains factor II, VII,
IX, X). In little more than 20 years, the use of clotting
factor preparations for the treatment of hemophilia has
increased greatly. In 1969 the average yearly consumption
of factor VIII in the UK was 7,000 IU per patient [12].
By 1974 this had almost doubled [12] and increased again
by 30% from 1976 to 1980 [104]. In 1988 in the Nether-
lands the Central Laboratories and bloodbanks of the
Dutch Red Cross produced almost 40 million IU Factor
VIII, i.e. 30,000 IU per patient [30]. This growth reflects
the increasing number of patients äs well äs the increasing
intensity of treatment, with a shift from on-demand
treatment to prophylactic treatment for patients with a
high frequency of bleeding.
Refinements in the manufacturing process have led to
clotting preparations becoming more and more concen-
trated. The recent development of Factor VIII extracted
from plasma by monoclonal antibodies has made avail-
able a product of unparalleled purity [23,136]. This in-
crease in purity has its price: in Europe, the products
manufactured by the monoclonal antibody technique are
about 30% more expensive than 'conventional' Factor
VIII concentrates. Theoretical advantages of these ultra-
pure products that might counterbalance the high costs
have been postulated, e.g. a beneficial effect on the im-
mune system; however, neither this effect nor its possible
clinical relevance have been convincingly demonstrated.
Presently, the first Factor VIII products made by re-
combinant DNA techniques are being used to treat hemo-
philia patients [144]. These preparations are not made
from human blood and are therefore free of human viru-
ses. Theoretically, this new technique also opens the pos-
sibility to manufacture a modified clotting factor, with
properties differing from those of natural Factor VIII or
IX (e.g. an extended half-life or high activity after oral
intake).
Successful laboratory experiments on the transfer of
genes [58] makes one hopeful for the more distant future,
when gene therapy will one day be the final Step from life-
long Substitution treatment to a real eure for hemophilia.
Prophylactic treatment
Clotting factor administration for the prevention rather
than treatment of bleedings was first applied in the late
1960s, although prophylactic plasma transfusions had
been reported much earlier [2,61,90,105,137]. Using
data from the Dutch hemophilia surveys we estimated
that the number of patients receiving prophylaxis in the
Netherlands had almost doubled between 1972 and 1985,
äs shown in Fig. 2 [123]. In prophylactic treatment, the
patient receives clotting factor product infusions two (he-
mophilia B) or three (hemophilia A) times a week, aimed
at maintaining a clotting factor level of more than 1% of
the normal value (0.01 lU/ml) at all times. Since joint
damage is absent or mild in patients with moderate or
mild hemophilia, it has been suggested that prophylactic
therapy started at an early age could prevent joint dam-
age altogether [2,8,91,95,137]. In prophylactic therapy,
bleedings probably are not truly prevented, but arrested
at the earliest, subclinical phase. It has been shown that
prophylaxis reduces the number of manifest bleedings by
äs much äs 60% [8,9].
Although common sense dictates that prophylaxis
prevents or slows the progression of arthropathy, this has
not convincingly been demonstrated. It has been suggest-
ed that early treatment of all joint bleedings (at the first
sign, and at least within 2 h after onset) may also be high-
ly effective [1,24,25,34]. This remains an important is-
sue, since prophylactic treatment usually implies a large
increase in clotting factor consumption.
Home treatment
Home treatment, first introduced in the early 1970s, has
become one of the cornerstones of modern hemophilia
care [75,99,100]. In our latest survey we saw that the
majority of patients in the Netherlands now received their
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Fig. 2. Home treatment and prophylaxis in the Netherlands. The
percentage of patients leceiving prophylactic treatment and home
treatment are shown, for patients with severe and moderalely severe
hemophilia. The 1972 figures refer to a survey of 242 patients, the
1978 figures to 351 patients, while 559 patients with severe and
moderate hemophilia participated in the 1985 survey [110, 123]
infusions at home, administered either by themselves or
by household members (Fig. 2) [123]. Home treatment
has been shown to combine several advantages. First,
bleedings can be treated without delay, which may help
in preventing the development and progression of joint
damage. We found that the average delay between the on-
set of bleeding and the administration of a transfusion is
less than 2 h for patients on home treatment äs compared
to 3-4 h for patients who have to travel to a hospital
[109,143]. In countries less densely populated than the
Netherlands the time gain in home treatment will be even
higher.
Home treatment leads to a reduction in the days spent
äs hospital inpatients, with large savings in hospital fees
[76,122]. Home treatment apparently does not lead to a
higher consumption of Factor VIII or IX [76,100], We
estimated for the Netherlands that the number of trans-
fusions performed at home rose from 996 in 1972 to
29,680 in 1985, which implies an enormous decrease in
outpatient visits [123].
The most important benefit of home treatment is that
it greatly enhances the patient's possibilities to lead äs
normal a life äs possible. The independence offered by
home treatment leads to increased self-regard of hemo-
philia patients, a greater mobility in Job and vocation
choices and an increased participation in social activities
[100]. Home treatment has been reported to substantially
decrease days lost from school and work [73,77,100]. We
have shown that this even leads to differences in oppor-
tunities for employment: when we compared patients
who were employed and patients who were unemployed
and received disablement pensions, we noted that home
treatment äs much äs doubled the chance of employment
[Hl].
Mortality and life expectancy
Before 1960 patients with severe hemophilia had a life ex-
pectancy of only 25 years [59,70,119]. The availability of
Table 1. Life expectancy in hemophilia
Survival (cum. %)
Study period Country Author(s) Severity Life expect-
ancy (years)
1830-1920
1921-1940
-1940
-1940
1941-1960
1931-1957
1961-1980
1976-1980
1973-1986
Sweden
Sweden
Finland
Denmark
Sweden
Sweden
Sweden
United
Kingdom
The Nether-
lands
Larsson [70]
Larsson [70]
Ikkala et al.
[59]
Sjölin [119]
Larsson [70]
Ramgren
[102]
Larsson [70]
Rizza,
Spooner [104]
Rosendaal
et al. [112]
severe
severe
severe
severe
severe
severe
moderate
mild
severe
severe
severe
moderate
mild
11
23
17
18
28
25
38
50
57
69
63
65
69
Observation period (year)
Fig. 3. Mortality in hemophilia 1973-1986. Cumulative survival
over time is shown. The lower /ine ('observed') is the survival of the
cohort of 717 hemophilia patients; the upper line ('expected') is the
survival in a hypothetical cohort from the general male population,
adjusted for age. The distance from 100% is the mortality, 7.4%
observed and 3.5% expected (redrawn from [112])
clotting factor preparations has greatly increased the ex-
pected life span almost to normal (Table 1). We observed
43 deaths in a group of 117 hemophilia patients we fol-
lowed from 1973 to 1986 (mean follow-up 11 years), while
21 deaths were expected in a hypothetical cohort of non-
hemophiliacs of the same age distribution (Fig. 3). Mor-
tality in hemophilia is now twice äs high äs in the non-
hemophilic population [62,112], aside from AIDS mor-
tality which differs from country to country, dependent
on the number of patients infected. The relative increase
in mortality by two is approximately the same äs that
caused by smoking cigarettes and implies an eight-year
reduction in life expectancy.
During this Century, the number of living hemophilia
patients has increased fourfold because of the higher life
expectancy. In Western-Europe, just before World War II
there were only four hemophilia patients per 100,000 ma-
les [6, 55]. In 1960 there were 6.6 patients per 100,000 ma-
les [102], while now the prevalence is 13-18 per 100,000,
much closer to the prevalence at birth of 21 per 100,000
males [71,104,106,123]. When patients live longer, the
average age of the living patients increases. This was seen
in the Netherlands: in 1972 the average age was still 11
years lower than that of the general male population; in
1985 the difference was no more than 5 years (29 äs com-
pared to 34 years for the general male population) [110].
The most common cause of death in hemophilia still is
hemorrhage, although it no longer constitutes the sole
death cause: in our study it accounted for half of the
deaths [78,93,102,112,129,148]. In a recent report on al-
most a thousand deaths of hemophilia patients in the
USA from 1968 to 1979, it was observed that the ratio of
the number of deaths by ischemic heart disease over the
number of cancer deaths was much smaller than in the
general population [7]. It was not possible from this
study to conclude whether this was caused by an increased
mortality from cancer or a decreased mortality from
ischemic heart disease, since this was not a follow-up
study: the number of deaths could only be compared rel-
ative to each other [proportional mortality ratios (PMR)].
In our follow-up study on 717 hemophilia patients we
found that the mortality from malignancies was increased
(2.5 fold), while mortality from ischemic heart disease
was substantially (80%) lower than in the non-hemophilic
population [112]. Several other studies on mortality in
hemophilia also seem to show a deficit of deaths by myo-
cardial infarction [62,104,129], although this is clearly
not reflected in one Swedish study [72].
Subsequently, we showed that the low mortality of
ischemic heart disease could not be attributed to differ-
ences in other risk factors in hemophilia patients, e.g.
blood pressure, smoking and serum cholesterol [107].
These results led us to the conclusion that the low activity
of the factor VIII-IX complex in hemophilia offers pro-
tection against ischemic heart disease. The protection is
not complete, for autopsy series have shown that hemo-
philia patients develop atherosclerosis [37,120], while
myocardial infarctions in hemophilia patients have been
reported occasionally [18,19]. It is interesting to note that
the protection against ischemic heart disease occurs even
while hemophilia patients have higher blood pressures
than non-hemophilic males. In our study on risk factors
for ischemic heart disease we found that the hemophilia
patients were hypertensive twice äs often äs non-hemo-
philic men (defined according to WHO Standards), and
also more often used antihypertensive medication [107].
Presently, no explanation can be offered for this high pre-
valence of hypertension among hemophilia patients, al-
though a high frequency of renal disorders among hemo-
philia patients has been reported [36,39,74,97, 121,152].
In myocardial infarction, coronary thrombosis is the
final event after many years of atherosclerotic coronary
disease [149]. For the general population, it has been
shown that low levels of fibrinogen [63,146] and factor
VII [87], protect from coronary disease. In the Northwick
Park study [87] it was also found that individuals in the
general population in the highest tertile of factor VIII
levels had a 40% higher risk of myocardial infarction
than those in the lowest tertile. Although this association
was non-significant (p = 0.2), when viewed together with
our observations in hemophilia patients, it seems likely
that also in the non-hemophilic population, low factor
VIII levels protect against myocardial infarction.
Clinical and social progress
Our consecutive hemophilia surveys have provided us
with an overview of the improved life expectancy, physical
Status and social opportunities of hemophilia patients
since the early 1970s, brought about by the availability of
clotting products and the Implementation of prophylaxis
and home treatment. Table 2 shows the tremendous de-
crease in hospital use and absenteeism from school and
Table 2. Trends in hospital admissions and sick leave
Patients with severe and moderately
severe hemophilia
1972 1978 1985
(n = 242) (n = 351) (n = 559)
Inpatient hospital use
Average use (days a year)a 23 (2)
Admissions (%) 47
Duration of stay 49 (20)
(days per year)b
Sick leave
Absenteeism from school 36
(days per year)
Absenteeism from work 32 (18)
(days per year)
10 (2) 4 (1)
37 22
26(15) 16(13)
19 9
34 (18) 20 (15)
Data from national hemophilia surveys in the Netherlands [123]. In
brackets the figures for the general male population
'' Average of all patients
b
 Average for those patients who were admitted to a hospital
throughout one year
work [123]. In 1972 one out of every two patients needed
to be hospitalized, äs compared to only one out of every
five in 1985, while the number of days spent in hospital
decreased threefold.
Before clotting factor products were available, many
hemophilia patients did not receive adequate education,
because of frequent long absences due to bleedings [102].
Many hemophilia patients were unemployed, since they
were at a disadvantage due to their disability and lack of
education [65, 83, 84]. The consequences of poor educa-
tional opportunities have been shown in studies from
Scotland, where a high percentage of patients was un-
employed, while those who were employed were mainly
engaged in manual labor (55%, äs compared to 28% in
the Netherlands) [83, 84,140]. It was also noted that the
more severe the hemophilia, the more often the patient
was engaged in manual labor.
In the Netherlands nowadays hemophilia patients are
less often unemployed for economical reasons only, than
the average Durch male [140]. Furthermore, the patients
who are employed have obtained positions that are ap-
propriate for the education they have received and they
do not have to perform Jobs below their capacities. In this
respect it is important to note that in the Netherlands
hemophilia patients have achieved the same educational
level äs the general male population [123,139]. Table 3
shows the sharp decline in sick leave from school, that
has undoubtedly contributed to the high educational level
of Dutch hemophilia patients [123]. A similar positive
trend has been observed in the United Kingdom: the
younger patients showed better academic achievements
than the older patients [134].
In spite of these positive trends, many hemophilia pa-
tients still are not employed because of their physical Sta-
tus and depend on benefits from one of the social securi-
ty funds. In the Netherlands the percentage of patients
who received a disability pension even slightly increased
10
from 17% in 1972 to 22% in 1985, although this implied
a decline when related to the increase in the number of
these persons in the general population, which more than
doubled in the same period [38,123,124].
Antibodies to factor VIII or IX
Some patients respond to treatment by the development
of antibodies to clotting factors, the so-called Inhibitors.
Treatment of these patients in case of a bleeding may
prove extremely difficult, since infused clotting factors
will be neutralized by these antibodies. Inhibitor develop-
ment occurs mainly in patients who themselves produce
no clotting factor at all, i.e. patients with severe hemophi-
lia, although antibodies to factor VIII in mild hemophilia
have been reported [20,35]. Antibodies to the missing
clotting factor are far more often seen in hemophilia A
than in hemophilia B [11,26]. It is likely that Inhibitor de-
velopment is to some extent genetically predisposed [49].
About 5-15% of the patients with severe hemophilia
have antibodies to Factor VIII or IX [11,26,50,64,123].
Since these prevalence data do not take into account the
high mortality risk of inhibitor patients [12, 59,104,112],
the acutal risk of developing an inhibitor before age 20 is
probably äs high äs 15-24% [86,132].
Inhibitor patients have profited least from the avail-
ability of clotting factor preparations. In our follow-up
study over the period 1973-1986 the death risk of inhibi-
tor patients was five times äs high äs that of non-inhibitor
patients, i.e. a quarter of the inhibitor patients (average
age only 20 years at the begin of the study) died within
ten years of follow-up [112]. Since joint bleedings cannot
be adequately treated because of the inhibitor, these pa-
tients are often severely handicapped. Therefore, while
prospects for employment have improved for hemophilia
patients, we saw in the same study that the presence of
an inhibitor very often led to unemployment [111].
In the treatment of a bleeding episode in an inhibitor
patient, activated prothrombin complex concentrate
(FEIBA, Factor Eight Inhibitor Bypassing Activity) and
porcine factor VIII have proved useful [22,68,98,116,118].
The inhibitor titer can be brought down by the infusion
of high doses of factor VIII, äs well äs by cyclophospha-
mide treatment [21,81,92,145]. Recently, is has been
shown that in some patients the inhibitor response itself
may be eradicated by the repeated infusion of low doses
of Factor VIII [103,138].
Transfusion-transmitted disease
The clotting factor products used to treat hemophilia pa-
tients are prepared from donated human blood and may
therefore transmit infectious diseases. Transmission of
hepatitis (B äs well äs non-A non-B) and the acquired im-
munodeficiency syndrome (AIDS) are the most threaten-
ing.
Very few of the hemophilia patients who have ever re-
ceived clotting factor products are free of markers of
hepatitis B infection [128]. The large majority of hemo-
philia patients has also been infected with non-A non-B
hepatitis [43,47]. The number of infected patients, äs
well äs the percentage of patients demonstrating elevated
liver enzymes, may be somewhat lower in those treated
with cryoprecipitate than in those treated with large pool
concentrates [127]. Evidence of cirrhosis has been report-
ed in 15-38% of hemophilia patients [4,57]. In the USA
liver disease accounted for 9% of the deaths in hemophi-
lia patients between 1968 and 1979 [7]; surprisingly, in
our more recent study of mortality over the period
1973 — 1986 no deaths from liver disease were noted [112].
In 1982 it became apparent that the acquired immu-
nodeficiency syndrome (AIDS) can be transmitted by
blood transfusions [29]. The first case of AIDS in a
hemophiliac was reported in 1982 in the United States and
since then more than 2,000 cases among hemophiliacs
have been reported worldwide [29,150,151], of whom
many have died.
The percentage of patients infected with the human
immunodeficiency virus (HIV) differs widely from coun-
try to country. The highest prevalence is found in coun-
tries that predominantly used clotting products manu-
factured from the plasma of paid donors in the United
States [17, 89,114]. In the United States itself 90% of
severely affected hemophilia patients are seropositive, in
West Germany 53%, in the United Kingdom 39%
[3,42, 52]. In countries that predominantly used products
manufactured from local donors, the numbers of sero-
positive patients are much lower: Belgium 7% [54], Nor-
way 8% [44], the Netherlands 17% [109] and Finland 1%
[Ikkala, personal communication]. In France, 50% of
hemophilia patients have become HIV positive in spite of
a blood product supply predominantly of local origin [5].
Steps have been taken to reduce the risk of HIV trans-
mission from infected donors to hemophilia patients:
donors are asked to withdraw if they belong to one of the
risk groups of AIDS (i.e. male homosexuals or bisexuals,
intravenous drugusers, sexual partners of someone be-
longing to a risk group), all donations are tested for anti-
HIV antibodies, and in the production of clotting factor
products a virus-inactivation step has been introduced.
By adequate heat-treatment, pasteurization or solvent-
detergent inactivation techniques Factors VIII and IX
products can be manufactured that are free from the risk
of HIV transmission [40,115,130]. Since pasteurization
also inactivates hepatitis viruses [131], products inactiv-
ated by this method should be used in treating virgin pa-
tients (patients who have not received any transfusions
previously).
No other group has been hit äs hard by AIDS äs the
hemophilia patients, of whom in many countries the
majority is HlV-seropositive. AIDS has had a pro found
effect on the lives of many if not all hemophilia patients,
who often form closely knit groups, within families and
within treatment centers [53,109]. There are many in-
stances in which several members of one family became
infected with AIDS.
Among the HIV infected hemophilia patients are
many children. This poses additional problems, since
these boys have to live through puberty and adolescence
not only hindered in establishing relationships by their
hemophilia and its hereditary nature, but also by the
bürden of carrying an infectious and dreaded disease.
The World Federation of Hemophilia has recognized
the need for financial assistance for HIV infected hemo-
philia patients by establishing a committee to this effect.
In several countries some sort of financial Support has
been awarded based on pre-existing legislation, i.e. pro-
duct liability laws, äs in West Germany and Sweden, or
no-fault compensation, äs in Norway and Denmark. Spe-
cial support foundations, partly supported by govern-
ment funds, have been established in several other coun-
tries, such äs the United Kingdom, Austria and Australia.
Lawsuits have been brought against governments, clot-
ting factor producers (pharmaceutical companies, the
Red Cross) and hospitals by individual plaintiffs äs well
äs by groups, sometimes of hundreds of patients, äs in
the compensation Claims against the government in the
United Kingdom. Few of these litigations have proven
successful in court, although several are still undecided.
Out of court settlements have been an indirect success of
(possible) legal action in a few individual cases in the
United States, and for all infected hemophilia patients in
Germany, by an agreement between patients' organisa-
tions and clotting factor producers [15,31-33].
The prognosis for seropositive hemophilia patients
appears to be no different than that of individuals from
other risk groups: 25% of seropositive individuals will
progress to AIDS within eight to nine years [51]. In spite
of the tremendous research efforts of the past years, the
outlook for those infected with HIV has improved only
very little. A benificial effect has been demonstrated for
the antiviral agent zidovudine (formerly called AZT),
that decreases the occurrence of opportunistic infections
and improves survival time in patients with AIDS [46]. In
one study zidovudine was also shown to reduce the rate
of progression in asymptomatic HIV infected individ-
uals, especially those with low CD4-positive cell counts
[142]. It is still unclear whether this implies a true benefit
in long-term survival [41,48].
Since often the first manifestation of AIDS is a
Pneumocysüs carinii pneumonia (PCP), prophylaxis in
asymptomatic individuals seems recommendable [45,85].
This PCP prophylaxis consists of co-trimoxazol orally or
pentamidine spray Inhalation.
Conclusion
The introduction of products rieh in factor VIII or IX in
the late 1960s, and the subsequent Implementation of
home treatment and prophylaxis have greatly improved
the physical Status and the social opportunities of hemo-
philia patients. At present, feelings of optimism are over-
shadowed by the tragedy of AIDS that has befallen so
many hemophilia patients. Nevertheless, this AIDS epi-
demic will pass, be it after it has taken a large toll.
The future of hemophilia treatment holds many pro-
mises and many challenges. The newest clotting factor
products offer a purity unprecedented, but are expensive
and require more plasma per unit of Factor VIII pro-
duced. One of the challenges for the future will be to
secure treatment of hemophilia patients that is safe, ad-
equate and affordable for society. In this respect, history
has shown us not to place all our trust in the newest pro-
ducts, for new products carry new risks. It is also note-
worthy that the improvements in physical Status and qua-
lity of life of hemophilia patients over the past two dec-
ades were mostly achieved with simple and unpure cryo-
precipitate.
In 1975, the World Health Organization urged all
countries to develop a self-sufficient blood System, with
voluntary and unpaid donors. In Europe nowadays, there
are only a few, small self-sufficient countries, like Belgi-
um, Finland and the Netherlands, while most countries
more or less depend on the import of blood products
from the United States, which are commercially manu-
factured from plasma of paid donors. Although the
European Committee has declared itself in favor of self-
sufficiency, this may be threatened when Europe becomes
a common market in 1992. The use of plasma obtained
locally from voluntary and unpaid donors, which offers
a safeguard against the international spread of trans-
fusion-transmitted diseases, is also often preferred out of
motives of principle [135].
Hemophilia treatment is expensive, but the Invest-
ment pays. In this respect, hemophilia offers an excellent
example of a disease in which the benefits outweigh the
costs to a high extent. These gains that have emerged over
a period of only twenty years are to a large extent non-
material in nature. Nevertheless, the increase in opportu-
nities for employment on the one hand, and the reduction
of hospital admissions and chronic physical ailments on
the other, will also lead to material gains that in due cour-
se may outweigh the costs.
The life expectancy of hemophilia patients has be-
come almost normal, and therefore the group of hemo-
philia patients is now ageing and rapidly catching up with
the general population. This implies that even though the
progression of joint damage is slower than in the past, it
may accumulate over many years. Treatment of arthro-
pathy in a growing group of older hemophilia patients
will be one of the challenges in the years to come.
It was the best of times, it was the worst of times.
While on the one hand the prospects of hemophilia pa-
tients never have been better, on the other hand they have
never been worse for those who have been infected by
HIV. It is difficult to express confidence and hope for the
future, when for some the perspective is filled with des-
pair. We expect that the hemophilia patients born in the
present era will be able to lead lives no different than
other people.
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